<DOC>
	<DOCNO>NCT00006261</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy . Donor lymphocytes may attack destroy cancer cell . PURPOSE : This phase II trial study effectiveness combination chemotherapy , peripheral stem cell transplantation , donor lymphocyte infusion treat woman stage IV breast cancer .</brief_summary>
	<brief_title>Allogeneic Transplantation Using Mini-Conditioning Treatment Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine tumor response woman stage IV breast cancer achieve partial remission mini-conditioning regimen comprise fludarabine cyclophosphamide , follow allogeneic peripheral blood stem cell transplantation ( PBSCT ) , donor lymphocyte infusion ( DLI ) . II . Determine progression free survival patient achieve complete remission treatment regimen . III . Determine whether DLI exert graft versus tumor effect patient . IV . Determine acute delayed toxicity regimen patient . V. Determine rate durable hematologic engraftment patient treat regimen . VI . Determine incidence severity acute chronic graft versus host disease patient treat regimen . VII . Determine extent chimerism patient treat nonmyeloablative conditioning regimen . VIII . Determine rate quality immune reconstitution patient treat regimen . IX . Determine event free overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive salvage chemotherapy comprise docetaxel IV 1 hour doxorubicin IV several minute day 1 . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . Beginning within 4-10 week completion salvage chemotherapy , patient achieve complete partial remission stable disease receive mini-conditioning comprise fludarabine IV 30 minute day -8 -4 cyclophosphamide IV 2 hour day -3 -2 . Patients receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) mobilize allogeneic peripheral blood stem cell ( PBSC ) IV day 0 . Beginning day 120 PBSC transplantation , eligible patient receive unmobilized donor lymphocyte infusion ( DLI ) 15-30 minute . Treatment continue monthly total 3 DLIs absence grade III IV graft versus host disease marrow aplasia . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 30-50 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV epithelial breast cancer Must meet one follow condition : Complete partial remission stable disease follow chemotherapy radiotherapy Previously untreated disease No progressive disease prior therapy metastatic breast cancer Overexpression HER2 protein ( 2+ 3+ immunohistochemistry ) allow failed prior trastuzumab ( Herceptin ) therapy Measurable disease physical exam external imaging study OR Evaluable disease ( e.g. , abnormal bone scan ) Availability suitable HLAA , B , DR phenotypically identical sibling donor No active CNS disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 60 Sex : Female Menopausal status : Not specify Performance status : ECOG 0 1 Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,000/mm3* Platelet count least 100,000/mm3* * In patient receive docetaxel Hepatic : SGOT SGPT great 5 time upper limit normal ( ULN ) * Bilirubin great ULN* Alkaline phosphatase great 2.5 time ULN Alkaline phosphatase great 4 time ULN SGOT SGPT great ULN * In patient receive docetaxel Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : Left ventricular ejection fraction least 40 % MUGA scan No cerebrovascular accident Pulmonary : DLCO , FVC , FEV1 least 60 % predict Other : No active infection Not pregnant nursing Negative pregnancy test HIV negative No history allergic reaction taxane polysorbate 80 No grade 2 bad peripheral neuropathy No second malignancy within past 2 year except basal cell skin cancer , carcinoma situ cervix , tumor previously treat curative intent No clinically significant comorbid illnesses PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior autologous stem cell transplantation Chemotherapy : See Disease Characteristics No prior docetaxel At least 3 week since prior chemotherapy Prior doxorubicin allow cumulative dose less 250 mg/m2 Prior paclitaxel allow No 1 prior salvage chemotherapy regimen metastatic disease Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>